Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Q2 FY26 Earnings Presentation
21 slides from Alivus Life Sciences's earnings presentation, Nov 6, 2025
Slide 1: Cover letter to stock exchanges: Investor Presentation
November 06, 2025 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322
Slide 2: Investor Presentation Q2FY26
Investor Presentation Q2FY26
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Financial Performance Review
Financial Performance Review 3
Slide 5: Q2FY26 Highlights
Q2FY26 | Highlights “Our performance, this quarter, was fuelled by strong momentum in the non-GPL business, which delivered an impressive 39.7% YoY growth. Non-GPL business has shown a robust performance Dr. Yasir Rawjee over last four quarters, driven by healthy demand across key geographies includ
Slide 6: Q2 & H1 FY26 Performance
Q2 & H1 FY26 Performance Revenue EBITDA PAT EPS (In ₹ M illion) (In ₹ M illion) (In ₹ M illion) (In ₹) 21.3% 21.8% 22.1% 32.1% 30.1% 33.0% 20.2% 18.8% 28.2% 31.3% 6,496 6,418 1,419 1,370 2,085 6,018 5,880 11.57 2,008 1,301 11.18 1,939 1,215 10.60 1,813 5,069 9.91 953 1,429 7.78 Q2FY25 Q3FY25 Q4FY25
Slide 7: P&L Highlights | Q2 & H1 FY26
P&L Highlights | Q2 & H1 FY26 Particulars (In ₹ Million) Q2 FY26 Q1 FY26 QoQ Q2 FY25 YoY H1 FY26 H1 FY25 YoY FY25 Revenue from Operations 5,880 6,018 -2.3% 5,069 16.0% 11,898 10,955 8.6% 23,869 Gross Profit 3,391 3,315 2.3% 2,817 20.4% 6,706 5,825 15.1% 13,061 Gross Profit (%) 57.7% 55.1% +260 bps 5
Slide 8: Healthy Return Indicators
Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) 40% 34% 3.4 32% 29% 2.9 2.7 27% 2.5 2.4 FY22 FY23 FY24 FY25 H1FY26 FY22 FY23 FY24 FY25 H1FY26 • ROICE is tracking at ~29% – Capital employed driven by calibrated capex strategy and better margins • FATR is 2.4 times – Asset turn trend
Slide 9: Robust Growth & Steady Profitability
Robust Growth & Steady Profitability Revenue EBITDA PAT EPS (In ₹ Million ) (In ₹ M illion) (In ₹ M illion) (In ₹) EBITDA Margin PAT Margin 31.5… 31.4% 31.1% 21.6% 30.1% 30.0% 20.6% 20.3% 19.7% 39.63 38.43 38.11 7,172 4,857 6,863 23,869 4,709 6,712 35.63 4,670 18.6% 22,832 6,308 32.62 21,612 21,232
Slide 10: Business Performance Review
Business Performance Review 9
Slide 11: Segmental Performance | Generic API vs CDMO
Segmental Performance | Generic API vs CDMO Generic API CDMO (Revenue In ₹ M illio n) (Revenue In ₹ M illion) 5,966 5,941 434 5,513 5,464 364 300 4,739 278 240 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 • Generic API revenues in Q2FY26 saw a growth of • CDMO business saw a
Slide 12: Segmental Performance | GPL vs Non-GPL
Segmental Performance | GPL vs Non-GPL GPL % of Total Revenue Non-GPL % of Total Revenue (In ₹ M illion) (In ₹ M illion) 37.2% 33.6% 62.8% 72.4% 66.4% 74.6% 75.6% 4,645 4,492 2,181 4,443 27.6% 25.4% 4,315 1,888 24.4% 1,773 1526 3,181 1,437 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q2FY25 Q3FY25 Q4FY25 Q1FY
Slide 13: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Mix 13% 18% 14% 17% 19% 33% 30% 30% 31% 39% Emerging Markets Acute 87% 82% 86% 83% 81% Chronic Regulated 67% 70% 70% 69% 61% Markets Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 • Regulated markets contributed 81% in Q2F
Slide 14: Company Overview
LIFE SCIENCES Company Overview ¢
Slide 15: Global Footprint
Global Footprint • Filed 586 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 370+ 30+ 155 179 70+ 10+ 115 21 125+ 586 50+ 10+ DMFs and 93 23 (Brazil) CEPs 14 Regulated Emerging India - Mix of Regulated Number of C
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ M illion) North Therapy Europe Japan Brazil Australia ROW Total % of Total Revenue America CVS 39 40 4 23 11 41 158 CNS 43 26 8 18 3 21 119 Anti-Infective 21 11 3 3 3 14 55 3.6% Diabetes 10 5 - 9 - 16 40 3.4% 3.3% Dermatology 9 6 1 13 1 11 41
Slide 17: Quality Focused Manufacturing and R&D Infrastructure
Quality Focused Manufacturing and R&D Infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA ▪ R&D for new product (Finland), Romania (Europe) PMDA development and complex Ankl
Slide 18: Strategy Going Forward
LIFE SCIENCES Strategy Going Forward ¢
Slide 19: Strategy Growth Levers
Strategy Growth Levers 1 Gx API Business ✓ New product launches 2 ✓ Geographical expansion New Growth levers ✓ Focus on new markets becoming more regulated ✓ CDMO Ramp up ✓ Pursue 2nd source opportunities with top generic players ✓ Expand into complex API platforms 3 Capacity ✓ Iron compounds ✓ Onco
Slide 20: Future Capacity Expansion
Future Capacity Expansion Operational Expansion Type Division Location Status & Planned Capacity Timelines Brownfield API / Intermediate Ankleshwar Planned addition of ~100KL Capacity FY26 Brownfield API Dahej Planned addition of ~160KL Capacity FY26 Phase 1 – ~200 KL (Construction is in process) FY
Slide 21: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@alivus.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RUNJHUN JAIN SNEHA SALIAN Email: diwakar.pingle@in.ey.com Email: runjhun.jain1@in.ey.com Email: sneha2.salian@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68